Mineralys Therapeutics (MLYS) Net Cash Flow (2022 - 2026)

Mineralys Therapeutics has disclosed Net Cash Flow across 5 years of filings, most recently posting -$60.1 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$60.1 million, down 218.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$52.2 million (down 170.02% YoY), and the FY2025 annual result was $58.8 million, down 9.19% from the prior year.
• Net Cash Flow came in at -$60.1 million for Q1 2026 at Mineralys Therapeutics, down from -$44.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $115.9 million in Q3 2025 to a low of -$79.3 million in Q3 2022.
• The 5-year median for Net Cash Flow is $5.4 million (2022), against an average of $6.0 million.
• Across the five-year window, Net Cash Flow surged 832.74% in 2023 and plunged 365.83% in 2025, its largest moves.
• Mineralys Therapeutics' Net Cash Flow stood at $38.7 million in 2022, then sank by 195.48% to -$37.0 million in 2023, then soared by 145.46% to $16.8 million in 2024, then slumped by 365.83% to -$44.7 million in 2025, then plunged by 34.53% to -$60.1 million in 2026.
• The last three Net Cash Flow figures came in at -$60.1 million (Q1 2026), -$44.7 million (Q4 2025), and $115.9 million (Q3 2025), per Business Quant data.